HSPiP-QbD Enabled Optimized Tolterodine Lipid Nanoparticles with GastroPlus-Based in vivo Prediction and in vivo Studies for Controlled Drug Delivery
International Journal of Nanomedicine · 2026-11 · Volume 21 · 1-29
DOI: 10.2147/ijn.s632752 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026-11. Verfasst von Afzal Hussain und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Hussain, A., Webster, T. J., Siddique, M. U. M., & Ramzan, M. (2026). HSPiP-QbD Enabled Optimized Tolterodine Lipid Nanoparticles with GastroPlus-Based in vivo Prediction and in vivo Studies for Controlled Drug Delivery. International Journal of Nanomedicine, Volume 21, 1-29. https://doi.org/10.2147/ijn.s632752
Vancouver
Hussain A, Webster TJ, Siddique MUM, Ramzan M. HSPiP-QbD Enabled Optimized Tolterodine Lipid Nanoparticles with GastroPlus-Based in vivo Prediction and in vivo Studies for Controlled Drug Delivery. International Journal of Nanomedicine. 2026;Volume 21:1-29. doi:10.2147/ijn.s632752
BibTeX
@article{Hussain2026,
author = {Hussain, Afzal and Webster, Thomas J and Siddique, Mohd Usman Mohd and Ramzan, Mohhammad},
title = {HSPiP-QbD Enabled Optimized Tolterodine Lipid Nanoparticles with GastroPlus-Based in vivo Prediction and in vivo Studies for Controlled Drug Delivery},
journal = {International Journal of Nanomedicine},
year = {2026},
volume = {Volume 21},
pages = {1--29},
doi = {10.2147/ijn.s632752}
}
EUVIMED